|

Asciminib single agent Clinical Trials

2 actively recruiting trials across 2 locations

No change since June 2026

Also known as: ABL001

Pipeline

Phase 2: 1Phase 4: 1

Top Sponsors

  • Novartis Pharmaceuticals2

Indications

  • Chronic Myelogenous Leukemia2
  • Cancer2
  • Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive1
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive1
  • Lung Cancer1

Ann Arbor, Michigan1 trial

Asciminib Roll-over Study

Michigan Med University of Michigan

Phase 4

New Brunswick, New Jersey1 trial

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Rutgers Cancer Institute of New Jersey

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.